MedTrace Logo

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

NCT01872065 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-12-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ARC-520 in normal, adult volunteers.

Conditions

  • Healthy

Interventions

DRUG

ARC-520

DRUG

Placebo

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, MD, PhD · Nucleus Network Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-09-30
Completion
2014-11-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01872065 on ClinicalTrials.gov